A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial
Addiction · 2023
DOI: 10.1111/add.16163 ↗At a glance
Randomisierte kontrollierte Studie in Addiction, 2023. Written by Ximena A Levander and 6 co-authors. Institution: Oregon Health and Science University, Department of Medicine, Division of General Internal Medicine and Geriatrics, Addiction Medicine Section, Portl…. Major MEDLINE topics: Methamphetamine, Central Nervous System Stimulants. Cited 4 times so far (Crossref); 54 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, NCATS NIH HHS, AHRQ HHS.
Abstract (original language)
Background and Aims Socio‐cultural (gender) and biological (sex)‐based differences contribute to psychostimulant susceptibility, potentially affecting treatment responsiveness among women with methamphetamine use disorder (MUD). The aims were to measure (i) how women with MUD independently and compared with men respond to treatment versus placebo and (ii) among women, how the hormonal method of contraception (HMC) affects treatment responsiveness.
Design
This was a secondary analysis of ADAPT‐2, a randomized, double‐blind, placebo‐controlled, multicenter, two‐stage sequential parallel comparison design trial.
Setting
United States.
Participants
This study comprised 126 women (403 total participants); average age = 40.1 years (standard deviation = 9.6) with moderate to severe MUD.
Interventions
Interventions were combination intramuscular naltrexone (380 mg/3 weeks) and oral bupropion (450 mg daily) versus placebo.
Measurements
Treatment response was measured using a minimum of three of four negative methamphetamine urine drug tests during the last 2 weeks of each stage; treatment effect was the difference between weighted treatment responses of each stage.
Findings
At baseline, women used methamphetamine intravenously fewer days than men [15.4 versus 23.1% days, P = 0.050, difference = −7.7, 95% confidence interval (CI) = −15.0 to −0.3] and more women than men had anxiety (59.5 versus 47.6%, P = 0.027, difference = 11.9%, 95% CI = 1.5 to 22.3%). Of 113 (89.7%) women capable of pregnancy, 31 (27.4%) used HMC. In Stage 1 29% and Stage 2 5.6% of women on treatment had a response compared with 3.2% and 0% on placebo, respectively. A treatment effect was found independently for females and males ( P < 0.001); with no between‐gender treatment effect (0.144 females versus 0.100 males; P = 0.363, difference = 0.044, 95% CI = −0.050 to 0.137). Treatment effect did not differ by HMC use (0.156 HMC versus 0.128 none; P = 0.769, difference = 0.028, 95% CI −0.157 to 0.212).
Conclusions
Women with methamphetamine use disorder receiving combined intramuscular naltrexone and oral bupropion treatment achieve greater treatment response than placebo. Treatment effect does not differ by HMC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Oregon Health and Science University, Department of Medicine, Division of General Internal Medicine and Geriatrics, Addiction Medicine Section, Portland, OR, USA.
- Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
- Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Department of Family Medicine, University of California Los Angeles, Los Angeles, CA, USA.
- Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA.
ORCID profiles: Ximena A Levander, Ryan R Cook, Madhukar H Trivedi, Philip Todd Korthuis, Steven Shoptaw
Funding
- NIDA NIH HHS
- NCATS NIH HHS
- AHRQ HHS
- Agency for Healthcare Research and Quality
- National Institute on Drug Abuse
- U.S. Department of Health and Human Services
Cite
APA
Levander, X. A., Carmody, T., Cook, R. R., Potter, J. S., Trivedi, M. H., Korthuis, P. T., & Shoptaw, S. (2023). A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial. Addiction. https://doi.org/10.1111/add.16163
Vancouver
Levander XA, Carmody T, Cook RR, Potter JS, Trivedi MH, Korthuis PT, et al. A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial. Addiction. 2023. doi:10.1111/add.16163
BibTeX
@article{Levander2023,
author = {Levander, Ximena A and Carmody, Thomas and Cook, Ryan R and Potter, Jennifer S and Trivedi, Madhukar H and Korthuis, Philip Todd and Shoptaw, Steven},
title = {A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial},
journal = {Addiction},
year = {2023},
doi = {10.1111/add.16163}
}
EUVIMED